Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

Dr. Jian Zhang Discusses with Dr. Harbeck: Is Chemotherapy Necessary for ER+/HER2- Breast Cancer Patients with Low Genetic Risk but High Clinical Risk

The 18th St. Gallen International Breast Cancer Conference (SG-BCC 2023) was held in Vienna, the "City of Music," from March 15 to 18, 2023. Breast cancer experts from around the world gathered at this conference to discuss the most cutting-edge and controversial topics in the diagnosis and treatment of early-stage breast cancer, leading to the formation of the updated St. Gallen International Expert Consensus on Early Breast Cancer every two years. Oncology Frontier invited Dr. Jian Zhang from Fudan University Affiliated Cancer Hospital to have an in-depth discussion with Dr. Nadia Harbeck from the University of Munich on the topic of whether chemotherapy is needed for patients with low genetic risk but high clinical risk (ER+/HER2-) breast cancer.
Dr. Jia Wang & Dr. William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

Dr. Jia Wang & Dr. William Gradishar: Controversies in Surgical Treatment for Stage IV Breast Cancer Patients at Initial Diagnosis

There is currently a lack of consensus on whether surgical treatment should be performed for patients with stage IV breast cancer at the initial diagnosis. At the 18th St.Gallen Breast Cancer Conference (SGBCC 2023), a debate titled "Surgery of the primary for stage IV disease" garnered global expert attention. The debate was moderated by  Dr. William Gradishar from Northwestern University Feinberg School of Medicine in the United States, with  Dr. Rajendra Badwe from Tata Research in India and Professor Florian Fitzal from ABCSG-28 Research in Austria presenting opposing views on this issue. "Oncology Frontier" invited  Dr. Jia Wang from the Second Hospital of Dalian Medical University and Dr. William Gradishar from Northwestern University Feinberg School of Medicine to engage in an in-depth discussion on this topic.
Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

Dr. Massimo Federico: 10-Year Follow-up Results of Early FDG-PET Adaptive Treatment for Limited-Stage HL

At the International Malignant Lymphoma Conference (ICML 2023), Dr. Massimo Federico from University of Modena and Reggio Emilia, presented a captivating report on 10-Year Follow-up Analysis of the EORTC/LYSA/FIL H10 Randomized Intergroup Trial during the "Focus on Hodgkin Lymphoma" session. Oncology Frontier specially invited Dr. Federico for an in-depth interview on this topic.